Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Quipt Home Medical (NASDAQ: QIPT) has announced a strategic joint venture with three major health systems to acquire a 60% ownership stake in Hart Medical Equipment for $17-18 million. Hart generates $60 million in revenue and $7 million in Adjusted EBITDA, with 29 locations across Michigan and Ohio serving over 67,000 patients monthly.
The transaction marks Quipt's entry into Michigan and expands its presence in Ohio, bringing the company's expected annualized run-rate revenue to $300 million. The remaining 40% interest will be held by healthcare partners including Henry Ford Health, McLaren Health Care, and Blanchard Valley Health System. The deal embeds Quipt into the discharge processes of more than 19 hospitals and affiliated care facilities.
The transaction is expected to close by the end of Fiscal Q4 2025, with management anticipating Adjusted EBITDA margins to align with historical corporate averages within three quarters post-closing.
Quipt Home Medical (NASDAQ: QIPT) reported its fiscal Q3 2025 results, showing signs of stabilization with a return to positive quarter-over-quarter organic growth of 1.6%. Revenue reached $58.3 million, down 4.1% year-over-year, while Adjusted EBITDA was $13.7 million (23.5% of revenue).
The company maintained strong recurring revenue at 81% of total revenue and served 151,000 unique patients. Post-quarter, Quipt acquired a DME provider from Ballad Health for $6.6 million in annual revenue, expanding its presence across four branch locations and securing a Preferred Provider Agreement with access to 20 hospitals.
Despite posting a net loss of ($3.0 million), the company maintains a healthy balance sheet with a Net Debt to Adjusted EBITDA leverage ratio of 1.5x and total credit availability of $35.3 million.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S.-based home medical equipment provider specializing in respiratory care, has scheduled its fiscal Third quarter 2025 financial results announcement for August 11, 2025, after market close.
The company will host a conference call for investors on August 12, 2025, at 10:00 a.m. ET. CEO Gregory Crawford and CFO Hardik Mehta will lead the call, which will be accessible via toll-free numbers for Canada/US participants and through a live webcast on the company's investor relations website.
Quipt Home Medical (NASDAQ: QIPT) has announced a strategic acquisition of a durable medical equipment (DME) provider owned by Ballad Health for $1.6 million plus accounts receivable and inventory value. The acquired company generated $6.6 million in revenue for fiscal year 2025 and serves over 12,500 patients annually through four locations in East Tennessee and Southwest Virginia.
Alongside the acquisition, Quipt secured a Preferred Provider Agreement with Ballad Health, covering 20 hospitals across four states. This partnership provides immediate post-acute referral access and serves a region with a projected 10.2% growth in senior population by 2028. The acquisition is expected to achieve Quipt's historical Adjusted EBITDA margins within two quarters through operational efficiencies and clinical workflow integration.
Quipt Home Medical, a leading U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled its fiscal Second quarter 2025 financial results announcement for May 12, 2025, after market close.
The company's leadership team, including CEO Gregory Crawford and CFO Hardik Mehta, will host a conference call for the investment community on May 13, 2025 at 10:00 a.m. ET. Investors can join via:
- Canada/US Toll Free: 1 (833) 752 3722
- International: 1 (647) 846 8549
A live webcast will be available through the investor section of Quipt's website at www.quipthomemedical.com.
Quipt Home Medical Corp. (NASDAQ: QIPT) has announced its strategic priorities for 2025, focusing on enhancing shareholder value through multiple initiatives. The company plans to accelerate organic growth by expanding De Novo locations, following successful openings in Florida and Alabama, and deepening referral networks with healthcare providers.
Key strategic priorities include implementing a share repurchase program through Normal Course Issuer Bid (NCIB), reflecting confidence in the company's fundamentals. Quipt is also pursuing strategic M&A opportunities with healthcare systems through potential joint ventures and acquisitions, aiming to integrate home-based care within larger healthcare ecosystems.
The company is launching the Quipt Sales Accelerator program for advanced sales training and expanding its product portfolio with new respiratory offerings. At its Annual General Meeting, shareholders approved the re-appointment of BDO USA as auditor and elected four directors. The board approved grants of 425,000 stock options at US$2.37 per share and 2,478,753 restricted stock units under its 2024 Equity Incentive Plan.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, has announced a cooperation agreement with Kanen Wealth Management. Under this agreement, Kanen has withdrawn its intent to solicit proxies for four director candidates at the 2025 annual general meeting.
The agreement grants Kanen Board access rights while maintaining at least 3.5% ownership of outstanding shares, including quarterly discussions with the Board Chairman or non-executive director. A new Board committee will be established to review Kanen's recommendations on corporate governance and operations.
The agreement includes a customary standstill and voting commitment from Kanen. DLA Piper, Vinson & Elkins L.L.P., and Goodmans LLP serve as legal advisors, with Longacre Square Partners as strategic advisor.